NexTel Medical Corp. Clarifies and Expands Upon Remarks Made During Recent Online Discussion

Rhea-AI Summary

NexTel Medical (OTC:MAJI) issued a clarification about remarks made in a recent online audio discussion. The company and partner Xycota are finalizing a Material Transfer Agreement with Baylor University for a study on the anti-aging properties of Maxasome Plus, with product shipments for clinical testing scheduled to start next week after execution.

NexTel also plans to launch a Maxasome Plus formulation for household pets as its third commercial product later this year. Following contract renegotiations with its Japanese partner, NexTel’s equity stake increased from 70% to 75%, and 11,277,000 additional LMMY shares will be issued to the company. Management is preparing a shareholder‑requested corporate initiative linked to the November 2025 LMMY transaction, with details to follow.

Positive

• Equity stake in Japanese partner raised from 70% to 75%
• 11,277,000 additional LMMY shares to be issued to NexTel
• Planned launch of third commercial product, veterinary Maxasome Plus, later this year
• Baylor University clinical testing of Maxasome Plus scheduled to begin after MTA execution

Negative

• None.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ORLANDO, FL / ACCESS Newswire / August 6, 2026 / NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCID:MAJI) ("NexTel" or the "Company") is issuing a clarification regarding statements made during an audio stream hosted yesterday afternoon with @SuperRobotGX.

Baylor University Research Agreement Update

During the presentation, Dr. Hausman referenced a study evaluating the anti-aging properties of Maxasome Plus in collaboration with Baylor University. NexTel clarifies that while this initiative had not been previously announced, the Company and its partner, Xycota, are currently finalizing a Material Transfer Agreement (MTA). Upon execution, product shipments to Baylor University for clinical testing are scheduled to commence next week.

Expansion of Maxasome Plus Product Line

The Company also highlighted plans to expand its product offerings with the upcoming launch of a Maxasome Plus formulation specifically tailored for household pets. NexTel anticipates introducing this veterinary formulation as its third commercial product later this year.

Increased Equity Stake in LMMY and Strategic Initiatives

Additionally, the Company discussed recent developments regarding its international partnerships. Following productive discussions and contract renegotiations with its Japanese partner, NexTel's equity ownership has increased from 70% to 75%. As a result of this renegotiation, an additional 11,277,000 shares of LMMY stock will be issued to the Company.

NexTel management further confirmed that it is actively preparing to initiate a key corporate initiative requested by shareholders since the closing of the LMMY transaction in November 2025. Additional details regarding this initiative will be disclosed as developments progress.

About NexTel Medical Corp.

NexTel Medical Corp. is a medical technology and biotechnology enterprise focused on acquiring, integrating, and commercializing high-impact medical platforms, novel therapeutic delivery technologies, and healthcare innovations.

Media & Investor Contacts:

NexTel Medical Corp.
Investor Relations & Corporate Communications
Email: ir@nextelmedical.com
Website: www.nextelmedical.com

SOURCE: NexTel Medical Corp

View the original press release on ACCESS Newswire

FAQ

What clarification did NexTel Medical (MAJI) provide about the Baylor University Maxasome Plus study on August 6, 2026?

NexTel Medical clarified that it is finalizing a Material Transfer Agreement with Baylor University for a Maxasome Plus anti-aging study. According to NexTel Medical, once the MTA is executed, product shipments for clinical testing are scheduled to commence next week.

When will Baylor University begin clinical testing of NexTel Medical’s Maxasome Plus according to the August 2026 update?

Clinical testing is scheduled to start next week, once the Material Transfer Agreement is executed. According to NexTel Medical, product shipments of Maxasome Plus to Baylor University will begin immediately following completion of the MTA between NexTel, Xycota, and Baylor.

How did NexTel Medical’s equity stake in its Japanese partner change, and what does it mean for LMMY shares?

NexTel Medical’s equity ownership in its Japanese partner increased from 70% to 75%. According to NexTel Medical, this contract renegotiation will result in an additional 11,277,000 shares of LMMY stock being issued to the company, expanding its international partnership exposure.

What new Maxasome Plus product for pets is NexTel Medical (MAJI) planning to launch?

NexTel Medical plans to introduce a Maxasome Plus formulation tailored for household pets later this year. According to NexTel Medical, this veterinary product is expected to become the company’s third commercial product, expanding its Maxasome Plus product line into the animal health market.

What shareholder-requested corporate initiative is NexTel Medical preparing after the November 2025 LMMY transaction?

NexTel Medical is preparing to initiate a key corporate initiative requested by shareholders following the November 2025 LMMY transaction. According to NexTel Medical, specific details have not yet been released and will be disclosed as developments progress over time.

How many additional LMMY shares will NexTel Medical receive under the renegotiated Japanese partnership?

NexTel Medical will receive 11,277,000 additional LMMY shares as a result of renegotiating its Japanese partnership. According to NexTel Medical, this issuance follows the increase of its equity stake in the partner from 70% to 75% after recent contract discussions.